CLDXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Celldex Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$29.67+2.14 (+7.77%)
Close on Oct 19, 2026
- Market cap
- $2.31B
- P/E (TTM)
- –
- Dividend yield
- –
Celldex Therapeutics, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Contracts and grants | $1.45M | $7.01M | $6.61M | $2.30M | $4.62M | $5.12M | $3.10M | $6.20M | $9.59M | $4.61M | 93.7% | -79.3% |
| Product development and licensing agreements | $97.00K | $13.00K | $278.00K | $56.00K | $31.00K | $2.30M | $473.00K | $3.34M | $3.15M | $2.17M | 6.3% | +646.2% |
By region
From the segment and revenue-disaggregation notes of Celldex Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.